Annual report pursuant to Section 13 and 15(d)

Segment, Geographical and Other Revenue Information - Segment Reporting (Details)

v3.19.3.a.u2
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Segment Reporting Information [Line Items]      
Total revenues $ 68,458 $ 60,594 $ 50,024
Cost of product revenue 15,632 12,620 14,327
Research and development 33,873 29,978 29,659
Selling, general and administrative 31,502 29,291 29,008
Income (loss) from operations (12,549) (11,295) (22,970)
Depreciation and amortization (1,570) (1,147) (1,042)
Loss before income taxes (11,918) (10,915) (22,915)
Share-based compensation 6,943 7,889 7,091
Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 58,156 47,073 42,333
Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues 10,302 13,521 7,691
Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 68,458 60,594 50,024
Cost of product revenue 15,632 12,620 14,327
Research and development 32,658 29,109 28,954
Selling, general and administrative 10,684 8,309 7,371
Total costs and operating expenses (58,974) (50,038) (50,652)
Income (loss) from operations 9,484 10,556 (628)
Share-based compensation 2,998 2,929 2,514
Operating Segments | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 58,156 47,073 42,333
Cost of product revenue 15,632 12,620 14,327
Research and development 19,380 18,924 16,847
Selling, general and administrative 8,462 7,538 7,371
Total costs and operating expenses (43,474) (39,082) (38,545)
Income (loss) from operations 14,682 7,991 3,788
Share-based compensation 2,303 2,591 2,306
Operating Segments | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues 10,302 13,521 7,691
Cost of product revenue 0 0 0
Research and development 13,278 10,185 12,107
Selling, general and administrative 2,222 771 0
Total costs and operating expenses (15,500) (10,956) (12,107)
Income (loss) from operations (5,198) 2,565 (4,416)
Share-based compensation 695 338 208
Corporate, Non-Segment      
Segment Reporting Information [Line Items]      
Total costs and operating expenses (19,624) (20,324) (21,245)
Depreciation and amortization (1,778) (1,147) (1,042)
Share-based compensation 3,900 5,000 4,600
Product Sales      
Segment Reporting Information [Line Items]      
Total revenues 29,465 25,590 26,685
Product Sales | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 29,465 25,590 26,685
Product Sales | Operating Segments | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 29,465 25,590 26,685
Product Sales | Operating Segments | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues 0 0 0
Research and Development Revenues      
Segment Reporting Information [Line Items]      
Total revenues 38,993 35,004 23,339
Research and Development Revenues | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 38,993 35,004 23,339
Research and Development Revenues | Operating Segments | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 28,691 21,483 15,648
Research and Development Revenues | Operating Segments | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues $ 10,302 $ 13,521 $ 7,691